12-Month Lobbying Summary - In-house Corporation

• Subject matter details in previous versions

  Details Regarding the Identified Subject Matter

  Subject matters	Details	Categories
  Subject matters were not required to be associated with subject matter details when this content was submitted	Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Pharmaceutical pricing policy arising from the jurisdiction of the patented medicine prices review board (PMPRB).	Policies or Program

  Subject matters in previous versions

  • Aboriginal Affairs
  • Economic Development
  • Health
  • Industry
  • Research and Development
  • Science and Technology
  • Taxation and Finance

Government Institutions

• Agriculture and Agri-Food Canada (AAFC)
• Finance Canada (FIN)
• Global Affairs Canada (GAC)
• Health Canada (HC)
• House of Commons
• Indigenous Services Canada (ISC)
• Innovation, Science and Economic Development Canada (ISED)
• Patented Medicine Prices Review Board (PMPRB)
• Prime Minister's Office (PMO)

Communication techniques

Communication techniques that have been used or are expected to be used in the course of the undertaking:

• Oral communication
• Written communication

Senior Officers whose lobbying activities represent less than 20% of their Duties

• Mark Lewis, President and CEO | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

• Mehmood Alibhai, Director of Patient Access & Healthcare Policy | No public offices held
• Annie Beauchemin, Head, Market Access | No public offices held
• Eve Blanchet, Regional Manager/ QUE, Patient Access and Health Policy | No public offices held
• Gerald McCarron, Manager, External & Healthcare Affairs | No public offices held
• Andrew Ransom, Manager, Patient Access | No public offices held

• Lobbyists in previous versions

  Senior Officers whose lobbying activities represent less than 20% of their Duties

  • Andrea Sambati, President, CEO | No public offices held